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Pigment epithelium-derived factor (PEDF), a member of the serine protease inhibitor superfamily, has potent anti-
metastatic effects in cutaneous melanoma through its direct actions on endothelial and melanoma cells. Here we
show that PEDF expression positively correlates with microphthalmia-associated transcription factor (MITF) in
melanoma cell lines and human samples. High PEDF and MITF expression is characteristic of low aggressive
melanomas classified according to molecular and pathological criteria, whereas both factors are decreased in
senescent melanocytes and naevi. Importantly, MITF silencing down-regulates PEDF expression in melanoma cell
lines and primary melanocytes, suggesting that the correlation in the expression reflects a causal relationship. Inted transcription factor; RGP, radial growth phase of melanoma; VGP, vertical growth
lanoma; BRAF, v-raf murine sarcoma viral oncogene homolog B; NRAS, neuroblastoma
geneous nuclear RNA
ad Autónoma de Madrid (UAM) and Instituto de Investigaciones Biomédicas Alberto
m.es
upplementary data related to this article.
nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-ncnd/3.0/).
530 Regulatory and functional connection of MITF and PEDF in melanoma Fernández-Barral et al. Neoplasia Vol. 16, No. 6, 2014agreement, analysis of Chromatin immunoprecipitation coupled to high throughput sequencing (ChIP-seq) data
sets revealed three MITF binding regions within the first intron of SERPINF1, and reporter assays demonstrated
that the binding of MITF to these regions is sufficient to drive transcription. Finally, we demonstrate that
exogenous PEDF expression efficiently halts in vitro migration and invasion, as well as in vivo dissemination of
melanoma cells induced by MITF silencing. In summary, these results identify PEDF as a novel transcriptional
target of MITF and support a relevant functional role for the MITF-PEDF axis in the biology of melanoma.
Neoplasia (2014) 16, 529–542Introduction
Pigment epithelium-derived factor (PEDF), a member of the serine
protease inhibitor (SERPIN) superfamily, is a 50 kDa secreted
glycoprotein that displays multiple biological activities relevant for
cancer biology [1,2]. PEDF was first described as a pro-differentiation
and survival factor in neuronal cells [3] and later was identified as the
most potent endogenous inhibitor of angiogenesis in the eye [4].
Evidence accumulated over the last decade consolidated its role as a
general anti-angiogenic factor in solid tumors [1,2]. Additionally,
PEDF impinges on proliferation, survival, migration and differenti-
ation of a broad spectrum of cancer cell types [1,2,5].
We have previously reported that PEDF has potent anti-tumor and
anti-metastatic activities in mouse models of melanoma as a
consequence of its combined actions: 1) in the tumor microvascu-
lature; hindering melanoma neovascularization through direct actions
on endothelial cells and indirect actions modulating the angiogenic
profile of melanoma cells; 2) in the melanoma cells; restricting their
survival, migratory and invasive capabilities [5,6]. Using a combina-
tion of gene expression profiling analysis and functional assays we
have also demonstrated that loss of PEDF expression enables
melanoma cells to acquire a migratory and invasive phenotype and
consequently it contributes to the metastatic spread of melanoma [7].
Despite the demonstrated relevance of PEDF in melanoma biology,
the mechanisms underlying the variations of PEDF levels during
malignant progression of melanoma are still largely unknown. In this
regard we have recently shown that hypoxia, a condition frequently found
in solid tumors and associated to malignant progression, negatively
regulates PEDF expression in melanocytes and melanoma cells [8].
Here, we aimed to investigate the regulatory mechanisms
controlling PEDF expression in the context of melanoma maligniza-
tion and melanocyte senescence.
Microphthalmia-associated transcription factor (MITF) has been
established as a master regulator of melanocyte and melanoma biology
[9–11]. MITF functions as a rheostat to determine different
biological responses in melanocytic cells depending on the level of
MITF expression and its post-translational regulation [12,13]. Very
low MITF levels lead to G1 arrested cells with invasive and stem-like
properties [12,14]. Moderate levels of MITF are required for
melanocytic cell proliferation [12]. By contrast, elevated MITF levels
drive the expression of lineage specific differentiation genes like TYR
[9]. In the context of melanoma progression, decreased MITF levels
lead to acquisition of invasive properties; whereas high MITF levels
favor less aggressive melanoma cells likely more sensitive to
therapeutic strategies [15].
The striking similarities in the multiple functional effects described
for PEDF and MITF in melanocytic cells prompted us to investigatewhether a regulatory and functional link between MITF and PEDF is
operative in melanocytic cells.
Herein, we describe that the expression of PEDF and MITF
positively correlates and varies with the pathological and molecular
staging of melanoma and in the context of melanocyte senescence.
Using a combination of approaches we demonstrate that MITF is a
direct positive regulator of PEDF expression in melanocytic cells.
And finally, we identify PEDF as a novel functional mediator of
MITF in the control of melanoma cell migration, invasion and
metastatic dissemination.Materials and Methods
Cell Lines and Cell Culture
Human melanoma cell line 501mel was provided by C. Bertolotto
(Institute de Génétique et de Biologie Moléculaire et Cellulair,
Illkirch, France) and cultured as described [16]. WM278, WM164,
WM88 and 1205Lu melanoma cell lines were provided by M. Herlyn
(The Wistar Institute, Philadelphia, PA, USA) and cultured as
described previously [17]. M000921, M080306 and M010308
melanoma cell lines were provided by K. Hoek (University Hospital
of Zürich, Zürich, Switzerland) and cultured as described [18].
MaMel69, MaMel82 and MaMel26a1 melanoma cell lines provided
by D. Schadendorf (Skin Cancer Unit of the Dermatology
Department, University Hospital, University Duisburg-Essen,
Germany) were cultured in RPMI (Gibco, Carlsbad, CA, USA)
medium supplemented with 10% FBS. HEK293T cell line was
cultured in DMEM (Gibco) medium supplemented with 10% FBS.
Primary human melanocytes (NHEM) were obtained from Lonza
(Basel, Switzweland) and cultured in MBM-4 medium with MGM-4
supplements (Lonza).
Melanoma cell lines were classified as weakly or highly aggressive
according to the molecular profiling analysis by K. Hoek and
collaborators [19]. Molecular profiling classification was validated by
functional assays in representative cell lines from the weakly aggressive
and highly aggressive cohorts [7,18].Western Blot
Whole-cell extracts were prepared by lysing the cells in 125mMTris-
HCl pH 7.5 and 2% SDS buffer containing protease and phosphatase
inhibitors (10 μg/ml leupeptin; 10 μg/ml aprotinin; 1mM sodium
orthovanadate; 1 mM PMSF (all from Sigma, St Louis, MO, USA)).
Conditioned medium was concentrated as described [20]. Concen-
trated or direct conditioned medium and whole-cell extracts were
separated by SDS-PAGE, transferred to PVDF membranes and
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and dilutions are listed in Supplementary Table 1.
RNA Extraction and Quantitative PCR
Total RNA was extracted and purified with the RNeasy Mini Kit
(Quiagen, Hilden, Germany) and retrotranscribed to cDNA using
high-capacity cDNA Archive Kit (Applied Biosystems, Foster City,
CA, USA). For hnRNA extraction, samples were pretreated with
DNAse I (Quiagen). See Supplementary Methods for TaqMan
probes and oligonucleotides used. The quantitative PCR reaction was
performed in an ABI Prism 7900 HT (Applied Biosystems).
Microarray Data Analysis
Published DNA microarray data sets comprising series of
melanoma cell lines were downloaded from public database (GEO
accession numbers: Mannheim GSE4843; Philadelphia GSE4841)
[19] and analyzed as described in [7].
Lentivirus Production and Transduction of Cell Lines
Lentiviruses were produced and tittered as previously described [7].
For transduction of target cells, lentiviruses were used at multiplicity
of infection (MOI) of 5-100 depending on the cell line, for 5-8 h,
resulting in more than 95% transduced (GFP-positive) cells.
RNA Interference and Over-Expression Strategies
MITF silencing was carried out using the lentiviral vector pGIPz
containing shRNAmir sequence V2LHS_257541 fromOpen Biosystems
(Thermo Fisher Scientific, Huntsville, AL, USA). Two additional
shRNAmir sequences were used: V2LHS_259964 and V2LHS_76565,
fromOpen Biosystems. Non-silencing shRNAmir sequence (shNS), with
no homology to knownmammalian genes was used as control, cloned in
a pGIPz vector (Open Biosystems). In order to carry out the MITF
silencing in 501mel melanoma cell line over-expressing PEDF, parental
cells were transduced with control lentiviral vector pRRL-GFP (GFP) or
lentiviral vector expressing PEDF, pRRL-PEDF (PEDF) [7], at 10MOI.
Seventy-two hours later, these melanoma cell lines were infected with
shNS or shMITF lentiviral vectors at 100 MOI. For MITF over-
expression we generated lentiviral constructs in the pCDH-CMV-MCS-
EF1-copGFP (kindly provided byH.Rizos [21]) encoding humanMITF
cDNA as indicated in Supplementary Methods.
Oncogene Induced Senescence (OIS)
OIS in melanocytes was carried out by transducing the lentiviral
plasmids indicated below at 5 MOI. pCDH-BRAFV600E lentiviral
plasmid [21] was provided by H. Rizos. We also generated lentiviral
constructs in the pRRL.CMV.EGFP.wpre.SIN vector encoding the
full-lengthHRASG12V cDNA as described in SupplementaryMethods.
Migration and Invasion Assays
Migration and invasion assays were performed seeding 120.000 cells
in modified Boyden chambers with polycarbonate filters (6.5 mm
diameter, 8.0 μm pore size) (Corning Incorporated, Corning, NY,
USA) coated with 0.5 % gelatin (migration assay) [6] or 15 μg growth
factor reducedMatrigel (BDBiosciences, Bedford,MA,USA) (invasion
assay) [7] diluted in 100 μl serum-freemedium, and air dried overnight.
Thirty or sixty μg/ml of concentrated conditioned medium (CM) from
NIH-3T3 cells was used as chemoattractant. After incubation for 16-24
h (migration assays) or 48 h (invasion assays), non-migrated and non-
invaded cells were wiped off using a cotton swab, and the filters were
stained with Diff Quik (Dade Behring, Newark, DE, USA). Migratedor invaded cells were counted in 10 fields of maximum migration or
invasion under a light microscope at 40x magnification.
Zebrafish Tumor Cell Dissemination Model
The metastatic ability of the tumor cell lines derived from
501mel cells in the zebrafish metastasis model was assayed as
described by P. Rouhi and collaborators [22,23]. Briefly, 501mel-GFP-
shNS, 501mel-PEDF-shNS, 501mel-GFP-shMITF and 501mel-PEDF-
shMITF cells were labeled in vitro with DiI dye and approximately
100-500 cells were injected per embryo in the perivitelline space of
2 days old transgenic Tg (fli1a:EGFP) zebrafish embryos. Z-stack
fluorescent micrographs were taken 3 days after melanoma cell
implantation and distally disseminated tumor cells were counted. All
experiments were performed in accordance with ethical permissions
granted by the North Stockholm Experimental Animal Ethical
Committee, Sweden.
Proliferation Assay
Melanocytes S-phase entry was analyzed by the incorporation of
5-ethynyl-2-deoxyuridine (EdU) at 20 μM for 6 h using the Click-iT
EdU Imaging Kit (Invitrogen, Carlsbad, CA, USA) as indicated by
the manufacturer. EdU-positive cells were counted in 10 different
fields at 20x magnification.
Immunofluorescence
Primary antibodies and dilutions are listed in Supplementary
Table 1. Primary melanocytes were seeded on glass coverslips in 24-
well plates at 2.104 cells per well. Cells were washed in PBS twice
and fixed with 4 % paraformaldehyde/PBS for 15 min at room
temperature. Cells were rinsed three times with PBS, then
permeabilized with 0.5 % Triton X-100/PBS-0.1 M glycine for 10
min, then rinsed and blocked with 3 % BSA/PBS for 1 h. Detection
of H3K9Me was performed incubating cells with rabbit polyclonal
antibody to H3K9Me for 16 h at 4ºC, then washed and incubated
with Alexa Fluor 546-conjugated secondary IgG (Invitrogen) and
DAPI (4’,6-diamidino-2-phhenylin-dole) for nuclei detection. Ten
fields at 40x magnification were counted. Immunofluorescence in
human samples for PEDF and MITF expression was performed on
formalin-fixed paraffin-embedded 3 μm sections from tissue
microarrays (TMAs) corresponding to naevus (n = 15),
RGP melanoma (n = 13), VGP melanoma (n = 19), cutaneous
metastases (n = 32) and visceral metastases (n = 17), retrieved from
Hospital 12 de Octubre Biobank. After deparaffinization, heat
antigen retrieval was performed in EDTA buffer, pH 9.0 using
DakoLink platform. Sections were immersed in TBS 5% BSA for 10
min to block non-specific binding and then, incubated with a rabbit
polyclonal antibody to PEDF and a mouse monoclonal antibody
against MITF. PEDF and MITF were detected using appropriate
Alexa Fluor 658 and 488 conjugated anti-rabbit and anti-mouse IgG
antibodies (Invitrogen). Sections were incubated with DAPI to
visualize cell nuclei. All incubations were performed at room
temperature (RT) using a Dako Autostainer. Fluorescence signals
were evaluated blindly by a trained pathologist using a Nuance FX
Multispectral Imaging System (Cri Caliper Life Sciences), which
compensates for unevenness in illumination and background, and
then flat fielded and filtered after image deconvolution the spectral
data. TIFF images were created. A semiquantitative HistoScore
(Hscore) was calculated for nuclear MITF and cytoplasmic PEDF
expression in target cells considering the percentage of melanocytic
532 Regulatory and functional connection of MITF and PEDF in melanoma Fernández-Barral et al. Neoplasia Vol. 16, No. 6, 2014cells showing low, medium, or high fluorescence intensity. The final
score was determined after applying a weighting factor to each
estimate: Hscore = (low %) x 1 + (medium %) x 2 + (high %) x 3.The results ranged from 0 to 300. For group comparisons, low,
intermediate and high expression categories were defined establish-
ing a threshold at Hscores of 100 and 200. Additionally, we
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MITF in each sample. Extension of co-localization was determined
for each sample as percentage of MITF-positive cells showing PEDF
expression. Percentage of biopsies displaying different degrees of co-
localization (b25%, 25%-75% and N75%) was estimated in naevus
and pathological stages of human melanoma.
ChIP-Sequencing
To identify MITF binding sites in the SERPINF1 locus, we analyzed
publicly available [24] and unpublished ChIP-seq data provided by I.
Davidson. Both ChIP-seq experiments were performed on chromatin
from native 501mel cells according to standard protocols as previously
described [24–26]. Peak detection was performed using the MACS
software (http://liulab.dfci. harvard.edu/MACS/; [27]) under settings
in which the HA–ChIP from untagged 501mel cells was used as a
negative control. Only peaks with an associated p-value below 10-5
were considered significant. The False Discovery Rate for the MITF
binding sites in the SERPINF1 locus was below 8%. To generate the
figures, the coordinates of the MITF binding sites and peak maximum
were uploaded into the UCSC genome browser (http://genome.ucsc.
edu/) as custom tracks in bed format [28].
Reporter Assays
Reporter assays were performed using WM278 and MaMel26a1
melanoma cell lines andHEK293T, all of themwith no basal expression
of MITF. Cells were seeded on 24-well plates (6.104 cells/well) 16 h
(HEK293T) or 48 h (WM278 and MaMel26a1) prior to transfection.
A mixture containing 0.6 μg of MITF expression vector (pCDH-HA-
MITF) or its control (pCDH-GFP), 0.15 μg of the indicated reporter
construct (described in Supplementary Methods) or empty plasmid and
0.03μg of a plasmid encoding for renilla luciferase under the control of a
minimal promoter (prolactin-) [29] was used for transfection with
Fugene (Promega). Analysis of firefly and renilla luciferase was
performed using the Dual Luciferase Reporter System (Promega) in a
Lumat LB9507 luminometer (Berthold Technologies, Bad Wildbad,
Germany). The luciferase activity was normalized to renilla activity
(constitutive expression). The results are represented as the average of the
fold induction obtained from three independent experiments in each cell
line and error bars represent the standard deviation.
Statistical Analysis
Statistical analysis was performed using GraphPad Instat
(GraphPad Software, San Diego, CA, USA). P-values b 0.05 were
considered as significant.
Results
MITF and PEDF Expression Positively Correlate During
Human Melanoma Progression and Melanocyte SenescenceFigure 1.MITF and PEDF expression in weakly aggressive and high
expression using microarray gene expression data of Mannheim ser
signature into weakly and highly aggressive cohorts. NormalizedMITF
the sample set. (B) Scattergram showing the positive correlation b
series. Statistical significancewas determined byPearson’s test (r= 0.4
(**P b 0.01) (right) expression in weakly and highly aggressive melan
determined by Welch’s test. Boxes in the plots include values in the 25
outliers. (D) Analysis of MITF and PEDF expression using microarray g
(E) Scattergram showing the positive correlation between MITF and
significancewas determined by Spearman’s test (r = 0.4762; *P b 0.05)
PEDF (Welch’s test; **P b 0.01) (right) expression in weakly and highlyPreviously, we used gene expression profiling analysis of large series
of melanoma cell lines to demonstrate that PEDF expression varied
with the molecular staging of melanoma cells, with high levels of
PEDF being characteristic of the weakly aggressive cohort [7]. Here we
extended this analysis to search for factors that positively correlate with
PEDF and that could therefore be candidate regulators implicated in
maintaining high PEDF levels in melanocytes and weakly aggressive
melanoma cells. In this analysis we found that expression of PEDF
positively correlated with MITF in two large melanoma sets
(Figure 1B and E). Figure 1A and D show that the cohort of weakly
aggressive melanomas is characterized by high levels of PEDF and
MITF, whereas the expression of both factors is significantly decreased
in the highly aggressive cohort (Figure 1C and F).
We next evaluated whether both factors also positively correlate in
human biopsies of different pathological stages of melanoma by
performing double immunoflourescence in tissue microarrays
(TMAs) of naevus (n = 15), radial growth phase (RGP) melanoma
(n = 13), vertical growth phase (VGP) melanoma (n = 19), cutaneous
metastases (CM) of melanoma (n = 32) and visceral metastases (VM)
of melanoma (n = 17) (Figure 2). As expected, we detected nuclear
MITF expression and cytoplasmatic PEDF expression (Figure 2A).
PEDF and MITF expression was variable in primary melanomas and
metastases, ranging from moderate to high (Figure 2A-B). However,
homogeneous and low expression of both factors was detected in
naevus; and high expression for either PEDF or MITF was not
detected in any naevus sample (Figure 2A-B). Expression of PEDF
and MITF was significantly increased in primary melanoma (RGP or
VGP melanoma) compared to naevus (Figure 2C). Also a significant
decrease in PEDF and MITF expression was observed in VGP
melanoma, cutaneous and visceral metastases compared to RGP
melanoma (Figure 2C). Furthermore, a positive correlation of both
factors was confirmed comparing biopsies of the different pathological
stages of human melanoma progression (Figure 2D).
These results provide solid evidence for positive correlation
between PEDF and MITF levels and co-regulation of their expression
according to molecular and pathological staging of melanoma.
Additionally, we analyzed by double immunofluorescence PEDF
and MITF co-localization within melanocityc cells in samples of
human naevus and melanoma (Figure 2A and E-F). In naevus, where
a mean of 50.3% of the total area of the sample expressed PEDF and
32.2% MITF, we observed that in average 85.5% of MITF-positive
cells also expressed PEDF (Figure 2E). Analysis of distribution of the
samples according to the degree of co-localization showed that PEDF
and MITF co-localized in the majority of the samples (Figure 2F).
Similar results were also found in primary melanoma and metastases
(Figure 2E-F).
In agreement with our results, it has been reported that MITF
expression is decreased in benign naevi [12,30,31]; which arely aggressive melanoma cell lines. (A) Analysis ofMITF and PEDF
ies of melanoma cell lines. Cell lines were classified by their gene
(empty bars) and PEDF (filled bars) signal intensity are plotted across
etween MITF and PEDF levels in each cohort of the Mannheim
145; **P b 0.01). (C) Box-plot ofMITF (****P b 0.0001) (left) andPEDF
oma cell lines of the Mannheim series. Statistical significance was
-75% interval; internal lanes represent the median; circles represent
ene expression data of Philadelphia series of melanoma cell lines.
PEDF levels in each cohort of the Philadelphia series. Statistical
. (F) Box-plot ofMITF (Mann-Whitney’s test; ****P b 0.0001) (left) and
aggressive melanoma cell lines.
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cytes in response to oncogenic mutations on BRAF or NRAS [32–34].
However, the association of PEDF down-regulation with senescencewas unknown and therefore we directly addressed whether PEDF was
regulated during oncogene-induced senescence (OIS) in primary
cultures of melanocytes.
Figure 3. Oncogene induced senescence promotes PEDF and MITF down-regulation in primary melanocytes. (A) Phase-contrast
images (20x magnification) showing the morphology of primary melanocytes (NHEM) transduced with control (pRRL or pCDH) and pRRL-
HRASG12V (HRASG12V) and pCDH-BRAFV600E (BRAFV600E) lentivirus. (B) Fluorescence images (40x magnification) showing chromatin
condensation (DAPI) and H3K9Me marks at day 6 post-infection of control or HRASG12V/BRAFV600E-expressing melanocytes.
(C) Percentage of cells showing heterochromatin foci. Bars represent average +/- standard deviation (SD). (D) Proliferation assay by
5-ethyl-2-deoxyuridine (EdU) incorporation at day 6 post-infection of control and HRASG12V/BRAFV600E-expressing melanocytes. Bars
represent average +/- SD. (E) Western blot analysis of extracellular PEDF (PEDFe) protein levels in concentrated conditioned
medium (CM), intracellular PEDF (PEDFi), RAS, BRAF, MITF, and p16 protein levels in whole-cell extracts from control and HRAS
G12V/
BRAFV600E-expressing melanocytes. β-tubulin was used as loading control. (F-G) Quantitative RT-PCR analysis of PEDF (F) and MITF
(G) mRNA levels in control and HRASG12V/BRAFV600E-expressing melanocytes. PEDF andMITFmRNA levels are shown relative to control
melanocytes (pRRL or pCDH) after normalization to 18s rRNA levels. Bars represent average +/- SD. Data shown are from a representative
experiment that was confirmed in three independent experiments, and statistical significance was determined by one-way ANOVA using
Tukey-Kramer post-test (***P b 0.001).
Figure 2. PEDF and MITF expression in human melanoma samples. (A) Representative images (40x magnification) corresponding to
double immunofluorescence of PEDF (green) and MITF (red) expression in tissue microarrays (TMAs) from naevus, radial growth phase
(RGP) melanoma, vertical growth phase (VGP) melanoma, cutaneous metastasis (CM) of melanoma and visceral metastasis (VM) of
melanoma. PEDF was detected in the cytoplasm and MITF in the nucleus of melanocytic cells. (B) Percentage of cases with low,
intermediate and high Hscore for PEDF and MITF in naevus, RGP, VGP, CM and VM of melanoma. (C) Quantification of MITF (empty bars)
andPEDF (filled bars) expression expressed asHscore in naevus, RGP, VGP, CMandVMofmelanoma. Bars represent average+/- standard
deviation (SD), and statistical significance was determined by one-way ANOVA using Tukey-Kramer post-test (**P b 0.01; ***P b 0.001).
(D) Scattergram showing the positive correlation between MITF and PEDF expression (Hscore) in human samples. Statistical significance
was determined by Pearson’s test (r = 0.841; ****P b 0.0001). (E) Percentage of area of expression ofMITF (empty bars), PEDF (black bars)
and co-localization (grey bars) in the collection of TMAs comprising naevus and pathological stages of melanoma progression. Bars
represent average +/- SD. (F) Percentage of biopsies displaying different degrees of co-localization (b25%, 25%-75% and N75%) of PEDF
and MITF in naevus and pathological stages of melanoma progression.
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Figure 4. MITF regulates PEDF expression in melanoma cell lines. (A) Transduction efficiency of 501mel melanoma cell line after
infection with non-silencing (shNS) or shRNAmir to MITF (shMITF) lentivirus at multiplicity of infection (MOI) of 100. Fluorescence
images (10x magnification) show more than 90% GFP-positive cells. (B) Quantitative RT-PCR of PEDF, MITF and TYR mRNA levels in
501mel-shNS and 501mel-shMITF melanoma cell lines. PEDF, MITF and TYR mRNA levels are shown relative to control shNS cells after
normalization to GAPDHmRNA levels. Bars represent average +/- standard deviation (SD), and statistical significance was determined by
Student’s test (***, P b 0.001; ****P b 0.0001). (C) Western blot analysis of extracellular PEDF (PEDFe) protein levels in concentrated
conditioned medium (CM), intracellular PEDF (PEDFi) and MITF protein levels in whole-cell extracts from 501mel-shNS and 501mel-
shMITF melanoma cell lines. β–tubulin was used as loading control. (D) Transduction efficiency of WM278 melanoma cell line after
infection with control (pCDH) and pCDH-HA-MITF (MITF) lentivirus at 100 MOI. Fluorescence images (10x magnification) showmore than
90% GFP-positive cells. (E) Quantitative RT-PCR of PEDF,MITF and TYRmRNA levels in WM278-pCDH and WM278-MITF melanoma cell
lines. PEDF, MITF and TYR mRNA levels are shown relative to control pCDH cells after normalization to 18s rRNA levels. Bars represent
average +/- SD, and statistical significance was determined by Student’s test (**P b 0.01). (F) Western blot analysis of PEDFe protein
levels (PEDF band indicated by an arrow) in direct conditioned medium (left), MITF and HA-tag protein levels (right) in whole-cell extracts
from WM278-pCDH, WM278-MITF and 501mel melanoma cell lines. β–actin was used as loading control.
536 Regulatory and functional connection of MITF and PEDF in melanoma Fernández-Barral et al. Neoplasia Vol. 16, No. 6, 2014Induction of senescence in primary melanocytes was evaluated
assessing characteristic morphological changes, presence of hetero-
chromatin foci and proliferation arrest [35] upon lentiviraltransduction of HRASG12V or BRAFV600E (Figure 3A-D). Human
primary melanocytes expressed high levels of PEDF and MITF that
decreased after induction of senescence by HRASG12V or BRAFV600E
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PEDF, as well as MITF protein was detected by western blot
(Figure 3E). p16INK4A was used as a marker of senescence in this
analysis [36] (Figure 3E). The changes in protein caused by OIS in
primary melanocytes were paralleled by decreased PEDF and MITF
mRNA levels as shown by quantitative RT-PCR (Figure 3F-G).
These results, together with the data from naevus, confirm that
PEDF and MITF expression are regulated with the same trend during
melanocyte senescence, both in vitro and in vivo.
MITF Regulates PEDF Expression in Melanoma Cell Lines
and Primary Melanocytes
To directly address the existence of a regulatory link between
MITF and PEDF, we silenced MITF by lentiviral transduction of a
shRNAmir specific for MITF in the following weakly aggressive
melanoma cell lines expressing high PEDF and MITF levels: 501mel
(Figure 4), WM164, M000921 and WM88 (Supplementary
Figure 1). Interference of MITF led to a significant down-regulation
of PEDF mRNA (Figure 4B and Supplementary Figure 1B) and
protein (Figure 4C and Supplementary Figure 1C). The extent of
PEDF down-regulation by MITF interference was similar to the
decrease in tyrosinase (TYR), a well known MITF target (Figure 4B
and Supplementary Figure 1B). PEDF down-regulation by MITF
interference was confirmed with two additional shRNAmir sequences
specific to MITF (data not shown).
Primary melanocytes express high levels of PEDF, similar to levels in
the weakly aggressive melanoma cell lines. We also found that MITF
interference decreased PEDF levels in primary human melanocytes
(Supplementary Figure 2).
Conversely, MITF over-expression by lentiviral transduction of
pCDH-HA-MITF in the WM278 melanoma cell line (which does
not express significant levels of MITF and PEDF mRNA) resulted in
increased mRNA and protein PEDF levels (PEDF band in WM278
cell line is indicated by an arrow) (Figure 4D-F).
PEDF is a Direct Target of MITF in Human Melanoma Cells
We next tested the hypothesis that PEDF is a direct transcriptional
target of MITF. Changes in gene expression due to increased
transcription rate are expected to be accompanied by increased
heterogeneous nuclear RNA (hnRNA), whereas changes due to
increased half-life of mRNA should not have an impact on hnRNA
levels. Therefore, we compared levels of hnRNA in a small collection
of melanoma cell lines representative of the weakly and highly
aggressive cohorts. As expected, mRNA levels of PEDF, MITF and
the MITF-target gene TYR were significantly higher in the weakly
aggressive cohort than in the highly aggressive cohort (Figure 5A-B).
PEDF and MITF hnRNA levels were significantly decreased in the
highly aggressive melanoma cell lines compared to the weakly
aggressive lines (Figure 5C-D), consistent with transcriptional
regulation. In agreement with the proposed role for MITF in the
transcriptional regulation of TYR, we found the expected trend in
hnRNA and mRNA, although it did not reach statistical significance
due to the high TYR hnRNA levels in one sample (MaMel69)
(Figure 5C-D).
To directly address the transcriptional regulation of PEDF by
MITF, we analyzed the data from a recently published MITF ChIP-
Seq (chromatin immunoprecipitation followed by high-throughput
sequencing) study [24] to identify MITF binding sites in the SER-
PINF1 locus. Three peaks of MITF binding were observed within thefirst intron of the SERPINF1 locus (Figure 5E, “Strub2011” track).
The binding of MITF to these three regions was confirmed by the
analysis of the unpublished data from an independent ChIP-Seq
experiment (Figure 5E, “New_MITF_ChIP-Seq” track). Important-
ly, these MITF binding sites lie within regions probably involved in
the regulation of the expression of this locus as indicated by their
sensitivity to DNase I (“DNase Clusters” track), presence of
experimentally determined binding sites for multiple transcription
factors (“Txn Factor ChIP” track), pattern of H3K27 acetylation
(“Layered H3K27Ac” track) and pattern of H3K4 methylation
(“Layered H3K4Me1” and “Layered H3K4Me3” tracks).
Finally, we performed reporter assays in HEK293T and two
aggressive melanoma cell lines (WM278 and MaMel26a1), which do
not express detectable levels of MITF and PEDF, to analyze the
functionality of the three binding regions identified by ChIP-Seq. All
three regions had the ability to increase the basal transcription of the
luciferase reporter gene under the control of a minimal promoter (data
not shown). However, only regions B and C, responded to exogenous
MITF (Figure 5F). Although, both regions B and C increased the
transcription of the reporter gene in response to MITF in HEK293T
and the two melanoma cell lines tested, the differences reached
statistical significance only in the case of region C (Figure 5F).
Altogether these results demonstrate that MITF regulates PEDF
transcription through direct binding to regulatory regions in the first
intron of SERPINF1 gene encoding for PEDF.
PEDF Mediates MITF Effects on Migration and Invasion of
Melanoma Cells
Regulation of the migratory and invasive potential of melanoma
cells is a fundamental driver of melanoma progression. Therefore, we
explored a possible functional connection between MITF and PEDF
in the control of melanoma cell migration and invasion. We
previously demonstrated that PEDF silencing consistently increases
migration and invasion capacity of melanocytes and melanoma cells
[7]. An analogous increase of the migratory ability of melanoma cells
was consistently observed with MITF silencing [12,37] in several
melanoma cell lines (Figure 6A and Supplementary Figure 3),
pointing to a possible functional role for the MITF-PEDF axis.
We next studied whether exogenous PEDF expression could
bypass the increased migration and invasion induced by MITF
silencing. To this end we transduced 501mel cells with lentivirus-
PEDF followed by MITF silencing by lentiviral transduction of
shRNAmir specific to MITF (Figure 6B-C). Figure 6D-E show that
exogenous PEDF expression efficiently blocks activation of migration
and invasion induced by MITF interference in 501mel cells,
indicating that the effect of MITF in migration and invasion of
melanoma cells is mediated, at least in part, by the regulation
of PEDF.
To further strengthen the functional connection between MITF
and PEDF and the relevance of the MITF-PEDF axis in the biology
of melanoma progression we have used the zebrafish metastasis
model. Figure 7 shows that silencing of MITF (501mel-GFP-
shMITF cells) increases the number of disseminated cells, while
simultaneous expression of exogenous PEDF (501mel-PEDF-
shMITF cells) efficiently counteracts this functional effect.Discussion
PEDF has emerged over the last decade as a dual action factor,
with a potent capacity to simultaneously modify the tumor
538 Regulatory and functional connection of MITF and PEDF in melanoma Fernández-Barral et al. Neoplasia Vol. 16, No. 6, 2014microenvironment and the behavior of the tumor cells [1,2,5]. PEDF
is a potent angiostatic factor for melanoma [6,38] and also an effective
molecular barrier to restrict the migratory and invasive capacity of
melanoma cells [7,39]. Despite its biological relevance in melanoma,
mechanisms underlying variations in PEDF expression during themalignant progression of melanoma are largely unknown. Recently,
we have described that microenvironment-derived signals like
hypoxia negatively regulate the expression of PEDF in melanocytic
cells [8]. Previously identified PEDF regulators in other cell types are
the members of the p53 family, p63 and p73 in colorectal cancer cells
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cancer cells [42] and retinoic acid and dexamethasone in several cell
types [43,44].
Here, we identifyMITF as amajor transcriptional regulator of PEDF
in the context of melanoma malignization and melanocyte senescence.
Using the information from high-throughput microarray studies
available at GEO data bases [7], here we identify a positive correlation
of PEDF and MITF expression in melanoma cell lines classified
according to molecular profiling criteria. PEDF and MITF are
differentially expressed in the cohorts defined by molecular profiling
and high levels of both factors are characteristic of the weakly
aggressive cohort. Therefore, these analyses support that high
expression of both factors restricts the metastatic potential of
melanoma cells, which has been directly demonstrated in mouse
models of melanoma [7,12,15,39]. Here, we further support this
conclusion by showing a positive correlation of PEDF and MITF
with the pathological staging of human melanoma.
A novel context in which we have found a link between PEDF and
MITF expression is melanocyte senescence. Induction of senescence
in melanocytes by forskolin treatment is associated with decreased
MITF expression [45,46]. Moreover, MITF silencing induces
senescence in melanoma cells [16,24]. Here we describe for the
first time that oncogene-induced senescence in primary melanocytes
down-regulates MITF and PEDF expression. In support of the
physiological relevance of this result, benign naevi; which are
considered senescent lesions [32,33], consistently showed decreased
levels of both PEDF and MITF compared to primary melanomas.
The anti-oxidant properties of PEDF [47–50] could be playing a role
in avoidance of melanocyte senescence. In this regard, it has been
recently reported that PEDF delays cellular senescence of human
mesenchymal stem cells by reducing oxidative stress [51]. Addition-
ally, PEDF could have an impact on the senescent secretome [36,52].
In support of this, we have previously demonstrated that exogenous
PEDF down-regulates the pro-senescent cytokine IL8 in melanoma
cells [53].Figure 5.MITF is a direct transcriptional regulator of PEDF expre
PEDF, MITF and TYR mRNA in a set of melanoma cell lines represe
shown relative to WM164 melanoma cell line after normalization to G
(SD). (B) Box-plot of PEDF (Welch’s test; *P b 0.05) (left),MITF (Welch’
mRNA levels in weakly and highly aggressive melanoma cell lines. Bo
represent the median, circles represent outliers. (C) Quantitative RT-
(hnRNA) in a set of melanoma cell lines representative of weakly
to WM164 melanoma cell line. Bars represent average +/- SD. (D) Bo
*P b 0.05) (middle) and TYR (Student’s test; ns) (right) hnRNA levels i
diagram depicting the human (hg19 assembly) genomic region cont
(http://genome.ucsc.edu/). The image includes two tracks, “Strub_
determined by ChIP-seq in two independent experiments ([24] and I. D
C accordingly to their proximity to ATG origin in first exon. These track
as a vertical red line within boxes. The remaining tracks show inform
curated databases (RefSeq), mono- and trimethylated H3K4 histone m
(H3K27Ac), DNase hypersensitive regions (DNase clusters), regions b
(Txn Factor ChIP) and regions bound by the glucocorticoid recepto
(Dx500pM NR3C1, Dx5nM NR3C1, Dx50nM NR3C1 and Dx100nM
dexamethasone (500 pM and 5 nM). The histone marks, DNase HS
across several cell types (see UCSC browser information ofr details
melanoma cell lines (right). Cell lines were transfected with control (p
constructs containing the indicated regions upstream of the firefly l
values of each construct and represented as fold change over the ac
Bars represent the average of values obtained in three independent e
way ANOVA using Tukey-Kramer post-test (*P b 0.05; **P b 0.01; **Oncogenic mutations in BRAF and NRAS are present in naevi as
well as in melanomas; suggesting that suppressive mechanisms of
senescence may also be contributing to maintain high PEDF
expression in weakly aggressive melanomas, in contrast to low
PEDF levels characteristic of senescent melanocytes in naevi. As BRAF
and NRAS mutations are mutually exclusive in melanoma, we also
analyzed whether they could underlie variations in PEDF expression.
Statistical analysis showed no significant association of PEDF
expression levels with BRAF or NRAS mutational status (P = 0.55).
Our finding of positive correlation and co-localization of PEDF
and MITF in human melanoma samples, prompted us to formally
address whether MITF could be a regulator of PEDF in the context of
melanoma. Here we show that MITF silencing down-regulates PEDF
expression in several melanoma cell lines and primary melanocytes.
Conversely, MITF over-expression increases PEDF levels in the
highly aggressive WM278 melanoma cell line. Subsequently, by
analysis of published and unpublished ChIP-seq data we identify
three MITF binding sites located in the first intron of SERPINF1.
Importantly, by means of reporter assays, we demonstrate that at least
two of these sites are functional in HEK293T and melanoma cells and
respond to MITF increasing transcription. Moreover, analysis of
publicly available information from the ENCODE project indicates
that MITF binding regions overlap with chromatin features
associated to transcriptional regulation, further supporting our
experimental data. Interestingly, region C overlaps with H3K4me1
chromatin mark and the binding site of the transcription factor
NR3C1, the endogenous glucocorticoid receptor (Figure 5E, NR3C1
tracks). Binding of NC3R1 to this region could explain the reported
regulation of SERPINF1 by dexamethasone [43,44]; suggesting that
region C is a functional regulatory element of the SERPINF1 locus.
Together these results demonstrate that MITF is a positive regulator
of PEDF in melanocytic cells.
Finally, we demonstrate a functional connection between
MITF and PEDF in the context of melanoma cell migration,
invasion and in vivo metastatic dissemination. We show thatssion in melanoma cell lines. (A) Quantitative RT-PCR analysis of
ntative of weakly and highly aggressive cohorts. mRNA levels are
APDHmRNA levels. Bars represent average +/- standard deviation
s test; **P b 0.01) (middle) and TYR (Student’s test; *P b 0.05) (right)
xes in the plots include values in the 25-75% interval; internal lanes
PCR analysis of PEDF, MITF and TYR heterogeneous nuclear RNA
and highly aggressive cohorts. hnRNA levels are shown relative
x-plot of PEDF (Student’s test; *P b 0.05) (left),MITF (Welch’s test;
n weakly and highly aggressive melanoma cell lines. (E) Schematic
aining the SERPINF1 gene obtained from UCSC genomic browser
2011” and “New MITF ChIP-Seq”, showing MITF binding sites
avidson unpublished data). Binding regions are named as A, B and
s represent the binding regions as grey boxes, and peaks summits
ation from the UCSC databases (from top to bottom): genes from
arks (H3K4Me1 and H3K4Me3) and acetylated H3K27 histone mark
ound by transcription factors experimentally assessed by ChIP-seq
r (NR3C1) in cells treated with 500 pM-100 nM dexamethasone
NR3C1). Note that no peaks are detected at lower doses of
regions and Txn Factor cluster tracks derive from the comparison
). (F) Reporter assays in HEK293T (left), WM278 and MaMel26a1
CDH-GFP) or MITF expression vector (pCDH-HA-MITF) and reporter
uciferase gene. The graphs show the corrected luciferase activity
tivity obtained in cells transfected with control vector (pCDH-GFP).
xperiments +/- SD. Statistical significance was determined by one-
*P b 0.001).
Figure 6. ExogenousPEDF expression blocks activationofmigration and invasion inducedbyMITF silencing. (A)Migration assay of
501mel-shNS and 501mel-shMITFmelanoma cell lines toward 0% FBS and 60 μg/ml of concentrated conditionedmedium (CM) fromNIH-
3T3 cells for 24 h. Bars represent average +/- standard deviation (SD), and statistical significance was determined by one-way ANOVA
using Tukey-Kramer post-test (***P b 0.001). (B) Quantitative RT-PCR of PEDF andMITFmRNA levels in 501mel-GFP-shNS, 501mel-PEDF-
shNS, 501mel-GFP-shMITF and 501mel-PEDF-shMITFmelanoma cell lines.PEDF andMITFmRNA levels are shown relative to control GFP-
shNS cells after normalization to GAPDH mRNA levels. Bars represent average +/- SD, and statistical significance was determined by
Student’s test (***P b 0,001). (C) Western blot analysis of extracellular PEDF (PEDFe) protein levels in direct conditioned medium,
intracellular PEDF (PEDFi) andMITF protein levels inwhole-cell extracts from501mel-GFP-shNS, 501mel-PEDF-shNS, 501mel-GFP-shMITF
and 501mel-PEDF-shMITF melanoma cell lines. β–actin was used as loading control. (D) Migration assay of 501mel-GFP-shNS, 501mel-
PEDF-shNS, 501mel-GFP-shMITF and 501mel-PEDF-shMITF melanoma cell lines toward 0% FBS (left) and 60 μg/ml CM from NIH-3T3
(right) for 24 h. (E) Invasion assay of 501mel-GFP-shNS, 501mel-PEDF-shNS, 501mel-GFP-shMITF and 501mel-PEDF-shMITF melanoma
cell lines toward 60 μg/ml CM from NIH-3T3 for 48 h. In migration and invasion assays bars represent average +/- SD, and statistical
significance was determined by one-way ANOVA using Tukey-Kramer post-test (***P b 0.001). Shown data are a representative
experiment that was confirmed in three independent experiments.
540 Regulatory and functional connection of MITF and PEDF in melanoma Fernández-Barral et al. Neoplasia Vol. 16, No. 6, 2014increased migration and invasion caused by MITF silencing could
be efficiently halted by exogenous PEDF expression in 501mel
cells, resulting also in a significant decreased dissemination in the
zebrafish metastasis model. Recently published results in retinal
pigment epithelial cells also demonstrate that silencing of PEDF
functionally compensates the inhibition of migration and invasion
caused by MITF over-expression [54]. Mechanisms involved in
inhibition of migration and invasion by MITF and PEDF are
poorly defined. Importantly, we have recently demonstrated that
PEDF abrogates the two main modes of melanoma invasion:
amoeboid and mesenchymal; through simultaneous inhibition of
RhoA and MT1-MMP triggered by the 34-mer epitope throughbinding to PNPLA2 receptor [39]. Both PEDF and MITF affect
the balance of Rho and Rac to inhibit melanoma cell migration
[12,39], although they impinge on melanoma invasion through
inhibition of different protease activities (MITF inhibits MMP2,
whereas PEDF blocks MT1-MMP) [12,39].
According to the phenotype switching model of melanoma
progression, metastasis is driven by the reversible reprogramming
of melanoma cells between proliferative and invasive phenotypes
[12,18,19]. MITF and PEDF were independently characterized as
important regulators of this switch [12,18]. Here, we identify a
regulatory and functional connection linking MITF and PEDF as
relevant brakes to melanoma malignization.
Figure 7. Sustained expression of PEDF halts in vivo dissemination of melanoma cells induced by MITF silencing. (A) Fluorescent
micrographs of the posterior tail showing distal dissemination of tumor cells (red) and their close association with the blood vessels of the
embryo (green) 3 days after melanoma cell implantation. Size bar indicates 100 micrometers. White arrowheads indicate disseminated
tumor cells. (B) The box-plots represent the number of distally disseminated tumor cells per fish (n = 21-25 fish/condition), 3 days after
melanoma cell implantation. Statistical significance was determined by one-way ANOVA using Tukey-Kramer post-test (***P b 0.001).
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